Novo Nordisk invests DKK 15.9bn to expand API production in Denmark
James Spargo | June 13, 2023 | News story | Manufacturing and Production | APIs, Chronic Diseases, Novo Nordisk, chronic diseases
Danish healthcare company Novo Nordisk has announced that it will invest another DKK 15.9bn into expanding an existing Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark. Construction has already begun, with production expected to start by early 2029.
The new 65,000m2 facility, which will create 340 new jobs, will be designed as a multi-product facility with maximum flexibility to accommodate new processes and display a state-of-the-art working environment and technology. It will allow the company to meet future market demands and develop clinical late-stage phase products.
The news comes as Novo Nordisk continues to struggle to meet manufacturing goals for its obesity drug, Wegovy. Global demand for the drug as risen considerably, with the UK Government recently announcing a plan to introduce it to the NHS.
Henrik Wulff, executive vice president of Product Supply, Quality & IT at Novo Nordisk, stated: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide. The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
James Spargo
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
